Table 2.
No. of Patients |
|||
---|---|---|---|
Course of Treatment | Trial 1 (n = 42) |
Trial 2 (n = 40) |
Trial 3 (n = 39) |
Second course of vaccine | 17 | 9 | 9 |
Second course of IL-2 | 17 | 7 | 4 |
Third course of vaccine | 15 | 5 | 1 |
Third course of IL-2 | 8 | 3 | 0 |
NOTE. Number of patients receiving therapy in subsequent 12-week courses. Vaccine could be administered without IL-2.
Abbreviation: IL-2, interleukin-2.